Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
SEROMYCIN
Overview
What is SEROMYCIN?
What does SEROMYCIN look like?
What are the available doses of SEROMYCIN?
Sorry No records found.
What should I talk to my health care provider before I take SEROMYCIN?
Sorry No records found
How should I use SEROMYCIN?
Seromycin is indicated in the treatment of active pulmonary and
extrapulmonary tuberculosis (including renal disease) when the causative
organisms are susceptible to this drug and when treatment with the primary
medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved
inadequate. Like all antituberculosis drugs, Seromycin should be administered in
conjunction with other effective chemotherapy and not as the sole therapeutic
agent.
Seromycin may be effective in the treatment of acute urinary tract infections
caused by susceptible strains of gram–positive and gram–negative bacteria,
especially spp. and . It is generally no more and is usually
less effective than other antimicrobial agents in the treatment of urinary tract
infections caused by bacteria other than mycobacteria. Use of Seromycin in these
infections should be considered only when more conventional therapy has failed
and when the organism has been demonstrated to be susceptible to the drug.
Seromycin is effective orally and is currently administered only by this route.
The usual dosage is 500 mg to 1 g daily in divided doses monitored by blood
levels. The initial adult dosage most frequently given
is 250 mg twice daily at 12–hour intervals for the first 2 weeks. A daily dosage
of 1 g should not be exceeded.
What interacts with SEROMYCIN?
Sorry No Records found
What are the warnings of SEROMYCIN?
Sorry No Records found
What are the precautions of SEROMYCIN?
Sorry No Records found
What are the side effects of SEROMYCIN?
Sorry No records found
What should I look out for while using SEROMYCIN?
Administration is contraindicated in patients with any of the
following:
Hypersensitivity to cycloserine
Epilepsy
Depression, severe anxiety, or psychosis
Severe renal insufficiency
Excessive concurrent use of alcohol
Administration of Seromycin should be discontinued or the dosage
reduced if the patient develops allergic dermatitis or symptoms of CNS toxicity,
such as convulsions, psychosis, somnolence, depression, confusion,
hyperreflexia, headache, tremor, vertigo, paresis, or dysarthria.
The toxicity of Seromycin is closely related to excessive blood levels (above
30 μg/mL), as determined by high dosage or inadequate renal clearance. The ratio
of toxic dose to effective dose in tuberculosis is small.
The risk of convulsions is increased in chronic alcoholics.
Patients should be monitored by hematologic, renal excretion, blood level,
and liver function studies.
What might happen if I take too much SEROMYCIN?
Acute toxicity from cycloserine can occur if more than 1 g is
ingested by an adult. Chronic toxicity from cycloserine is dose related and can
occur if more than 500 mg is administered daily. Patients with renal impairment
will accumulate cycloserine and may develop toxicity if the dosing regimen is
not modified. Patients with severe renal impairment should not receive the drug.
The central nervous system is the most common organ system involved with
toxicity. Toxic effects may include headache, vertigo, confusion, drowsiness,
hyperirritability, paresthesias, dysarthria, and psychosis. Following larger
ingestions, paresis, convulsions, and coma often occur. Ethyl alcohol may
increase the risk of seizures in patients receiving cycloserine.
The oral median lethal dose in mice is 5290 mg/kg.
To obtain up–to–date information about the treatment of overdose, a good
resource is your certified Regional Poison Control Center. Telephone numbers of
certified poison control centers are listed in the . In managing overdosage,
consider the possibility of multiple drug overdoses, interaction among drugs,
and unusual drug kinetics in your patient.
Overdoses of cycloserine have been reported rarely. The following is provided
to serve as a guide should such an overdose be encountered.
Protect the patient’s airway and support ventilation and perfusion.
Meticulously monitor and maintain, within acceptable limits, the patient’s vital
signs, blood gases, serum electrolytes, etc. Absorption of drugs from the
gastrointestinal tract may be decreased by giving activated charcoal, which, in
many cases, is more effective than emesis or lavage; consider charcoal instead
of or in addition to gastric emptying. Repeated doses of charcoal over time may
hasten elimination of some drugs that have been absorbed. Safeguard the
patient’s airway when employing gastric emptying or charcoal.
In adults, many of the neurotoxic effects of cycloserine can be both treated
and prevented with the administration of 200 to 300 mg of pyridoxine daily.
The use of hemodialysis has been shown to remove cycloserine from the
bloodstream. This procedure should be reserved for patients with
life-threatening toxicity that is unresponsive to less invasive therapy.
How should I store and handle SEROMYCIN?
Dispense in a well-closed container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Dispense in a well-closed container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Seromycin is available as a 250 mg capsule with an opaque red cap and opaque gray body imprinted with “CHAO” and “F04” in edible black ink on both the cap and the body. Bottles of 40 NDC 13845-1200-3 Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Seromycin is available as a 250 mg capsule with an opaque red cap and opaque gray body imprinted with “CHAO” and “F04” in edible black ink on both the cap and the body. Bottles of 40 NDC 13845-1200-3 Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Seromycin is available as a 250 mg capsule with an opaque red cap and opaque gray body imprinted with “CHAO” and “F04” in edible black ink on both the cap and the body. Bottles of 40 NDC 13845-1200-3 Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP].
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
After oral administration, cycloserine is readily absorbed from
the gastrointestinal tract, with peak blood levels occurring in 4 to 8 hours.
Blood levels of 25 to 30 μg/mL can generally be maintained with the usual dosage
of 250 mg twice a day, although the relationship of plasma levels to dosage is
not always consistent. Concentrations in the cerebrospinal fluid, pleural fluid,
fetal blood, and mother’s milk approach those found in the serum. Detectable
amounts are found in ascitic fluid, bile, sputum, amniotic fluid, and lung and
lymph tissues. Approximately 65 percent of a single dose of cycloserine can be
recovered in the urine within 72 hours after oral administration. The remaining
35 percent is apparently metabolized to unknown substances. The maximum
excretion rate occurs 2 to 6 hours after administration, with 50 percent of the
drug eliminated in 12 hours.
Non-Clinical Toxicology
Administration is contraindicated in patients with any of the following:Hypersensitivity to cycloserine
Epilepsy
Depression, severe anxiety, or psychosis
Severe renal insufficiency
Excessive concurrent use of alcohol
Administration of Seromycin should be discontinued or the dosage reduced if the patient develops allergic dermatitis or symptoms of CNS toxicity, such as convulsions, psychosis, somnolence, depression, confusion, hyperreflexia, headache, tremor, vertigo, paresis, or dysarthria.
The toxicity of Seromycin is closely related to excessive blood levels (above 30 μg/mL), as determined by high dosage or inadequate renal clearance. The ratio of toxic dose to effective dose in tuberculosis is small.
The risk of convulsions is increased in chronic alcoholics.
Patients should be monitored by hematologic, renal excretion, blood level, and liver function studies.
Cimetidine, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
Clinically significant effects have been reported with the warfarin anticoagulants; therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when cimetidine is administered concomitantly. Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.
However, a crossover study in healthy subjects receiving either 300 mg four times daily or 800 mg at bedtime of cimetidine concomitantly with a 300 mg twice daily dosage of theophylline (Theo-Dur®) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg at bedtime regimen, particularly in subjects aged 54 years and older. Data beyond ten days are not available. (Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.)
Dosage of the drugs mentioned above and other similarly metabolized drugs, particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping the concomitant administration of cimetidine to maintain optimum therapeutic blood levels.
Alteration of pH may affect the absorption of certain drugs (e.g., ketoconazole). If these products are needed, they should be given at least 2 hours before cimetidine administration.
Additional clinical experience may reveal other drugs affected by the concomitant administration of cimetidine.
Before treatment with Seromycin is initiated, cultures should be taken and the organism’s susceptibility to the drug should be established. In tuberculous infections, the organism’s susceptibility to the other antituberculosis agents in the regimen should also be demonstrated.
Anticonvulsant drugs or sedatives may be effective in controlling symptoms of CNS toxicity, such as convulsions, anxiety, and tremor. Patients receiving more than 500 mg of Seromycin daily should be closely observed for such symptoms. The value of pyridoxine in preventing CNS toxicity from Seromycin has not been proved.
Administration of Seromycin and other antituberculosis drugs has been associated in a few instances with vitamin B and/or folic–acid deficiency, megaloblastic anemia, and sideroblastic anemia. If evidence of anemia develops during treatment, appropriate studies and therapy should be instituted.
Most adverse reactions occurring during therapy with Seromycin involve the nervous system or are manifestations of drug hypersensitivity. The following side effects have been observed in patients receiving Seromycin:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
515Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).